Today, for the first time, Metamark presents results from the clinical validation study that showed ProMark™, the first and only proteomic-based imaging biopsy test, achieved its primary endpoint.

Researchers are constantly testing new medications for various conditions and breast cancer is no exception.

The US Food and Drug Administration today approved Gazyva ( obinutuzumab ) for use in combination with chlorambucil to treat patients with previously untreated chronic lymphocytic leukemia (CLL).

Pfizer Canada Inc. (manufacturer of Sutent), in collaboration with Health Canada, would like to inform you about an important revision to the Product Monograph, including the consumer information section, for Sutent (sunitinib malate).

GSK today announced that the US Prescription Drug User Fee Act (PDUFA) goal date for trametinib, its MEK inhibitor, has been extended by 3 months to 3 September 2013.

Pfizer Inc. announced today its investigational compound palbociclib (PD-0332991), an oral and selective inhibitor of cyclin dependent kinases (CDK) 4 and 6, has received Breakthrough Therapy designation by the United States Food and Drug Administration (FDA) for the potential treatment of patients with breast cancer.

Pfizer Inc. announced today that the European Commission (EC) has granted conditional marketing authorization for BOSULIF ® (bosutinib) in the European Union (EU) for the treatment of adult patients with chronic phase (CP), accelerated phase (AP) and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) (TKIs) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.

Peregrine Pharmaceuticals announced results from its 70 patient open-label, randomized Phase II clinical trial of bavituximab used in combination with gemcitabine in patients with previously untreated, advanced Stage IV pancreatic cancer.

GTx , Inc. today announced that the US Food and Drug Administration (FDA) has designated enobosarm ( GTx-024 ) for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer as a Fast Track development program.

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial of Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival.